MedTrace Logo

Vascular Inflammation and Cholesterol Lowering Therapy

NCT02941016 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2020-10-14

No results posted yet for this study

Summary

This study aim to detect change in vascular inflammation following intense lipid lowering therapy

Conditions

  • Lipid Lowering, Vascular Inflammation

Interventions

DRUG

Evolocumab or Alirocumab

All patients are treated with PCSK-9 inhibitors (Evolocumab or Alirocumab) to lower cholesterol

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Rasmus S Ripa, MD, DMSc · Rigshospitalet, Denmark

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2020-10-31
Completion
2020-10-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02941016 on ClinicalTrials.gov